These data indicated that targeting the suppression of SIRT3/mito-COX-2/p-Drp1Ser616 signaling axis-associated MQC regulation succeeds in addressing a novel, multi-pattern, anti-tumor target with which to increase chemosensitivity in HCC. Here, SIRT3 is linked to hepatocellular carcinoma.